US patient support groups Mended Hearts and Mended Little Hearts launch awareness campaign on atrial septal defects (ASDs) thanks to an unrestricted educational grant by atHeart Medical.
New patients are being enrolled in the ASCENT ASD pivotal trial, following US and EU regulatory authorization of trial expansion to Stage 3.
Vice-President Fabien Lombardi joined atHeart Medical to lead the R&D team driving forward next generation devices.
We are marking Children’s Heart Awareness Day in Switzerland to remember when most heart journeys begin: during infancy and childhood.
A Dabou Hospital in Ivory Coast is using 1200 medical gloves donated by atHeart Medical.
Ella suffered from migraine and severe fatigue as a teenager and now has a new life at college, following her ASD closure as part of the ASCENT-ASD trial.
The reSept ASD Occluder is featuring in an extensive article by Professor Tom Jones in the latest issue of Congenital Cardiology Today.
The reSept ASD Occluder has now been implanted in France and EU for the first time.
atHeart Medical has received approval for the start of the second phase of its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial.
The story of the first patient implanted with a reSept ASD Occluder in Switzerland.